雅虎香港 搜尋

登入

搜尋結果

  1. pubmed.ncbi.nlm.nih.gov › 29518013Immunogenicity and Safety of the New Inactivated ...

    2018年3月8日 · Vaxigrip Tetra is well tolerated, has aroused no safety concerns, and is recommended for the active immunization of individuals aged ≥6 months. In addition, preliminary data confirm its immunogenicity and safety even in children aged 6-35 months and its immunogenicity in older subjects (aged 66-80 years).

    • Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
    • 2018

  2. www.sanofi.com › assets › countriesPROFESSIONAL INFORMATION FOR VAXIGRIP TETRA - Sanofi

    VAXIGRIP TETRA is indicated for the prevention of influenza disease caused by the two influenza. virus subtypes and the two influenza B virus types contained in the vaccine for: active immunisation of adults, including pregnant women, and children from 6 months of age. and older,

  3. www.ncbi.nlm.nih.gov › pmc › articles4. A Novel Quadrivalent Inactivated Influenza Vaccine: ...

    2018年3月8日 · Vaxigrip Tetra is well tolerated, has aroused no safety concerns, and is recommended for the active immunization of individuals aged ≥6 months. In addition, preliminary data confirm its immunogenicity and safety even in children aged 6–35 months and its immunogenicity in older subjects (aged 66–80 years).

    • Emanuele Montomoli, Alessandro Torelli, Ilaria Manini, Elena Gianchecchi
    • 10.3390/vaccines6010014
    • 2018
    • Vaccines (Basel). 2018 Mar; 6(1): 14.

  4. www.news-medical.net › drugs › Vaxigrip-TetraVaxigrip Tetra Drug / Medicine Information - News-Medical.net

    1 天前 · Vaxigrip Tetra is a vaccine. This vaccine helps to protect you or your child against influenza (flu). Vaxigrip Tetra is used to prevent flu in persons of 6 months of age and older. If you are...

  5. www.ncbi.nlm.nih.gov › pmc › articlesBrand-specific estimates of influenza vaccine effectiveness ...

    2023年7月20日 · The most significant IVE estimates were 76% (95% CI 23%−93%) for any vaccine and 81% (22%−95%) for Vaxigrip Tetra in adults ≥65 years old and 64% (25%−83%) for Fluenz Tetra in children (TND primary care setting), 85% (12%−97%) for any vaccine in adults 18–64 years (TND hospital setting), and 38% (1%−62%) in children 6 months−6 years (population-...

    • 10.3389/fpubh.2023.1195409
    • 2023
    • Front Public Health. 2023; 11: 1195409.

  6. www.tga.gov.au › sites › defaultAttachment: Product Information for Inactivated quadrivalent ...

    Attachment 1: Product AusPAR - Vaxigrip Tetra - Inactivated quadrivalent influenza vaccine (split virion) - Sanofi-Aventis Australia Pty Ltd - PM-2018-00583-1-2 FINAL 19 December 2019. This

  7. www.chp.gov.hk › tc › features衞生防護中心 - 疫苗資助計劃詳情 - 接種季節性流感疫苗 - ...

    疫苗資助計劃詳情 - 接種季節性流感疫苗. 2023年9月5日. 2023／24年度季節性流感「疫苗資助計劃」已於2023 年 9 月 28 日展開，而「政府防疫注射計劃」、「季節性流感疫苗學校外展（免費）計劃」及「院舍防疫注射計劃」則會於2023 年 10 月 5 日開始。 長者接種肺炎球菌疫苗的安排會於全年繼續進行。 流行性感冒（流感）是由流感病毒引致的急性呼吸道疾病。 本港全年都有流感病例，但一般在一至三／四月及七至八月較為常見。 病毒主要透過呼吸道飛沫傳播，患者會出現發燒、喉嚨痛、咳嗽、流鼻水、頭痛、肌肉疼痛、全身疲倦等症狀。 患者一般會在 2 至 7 天內自行痊癒。